Literature DB >> 12858076

The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system.

Bert A 't Hart1, Sandra Amor.   

Abstract

PURPOSE OF REVIEW: A major hurdle in the research of neuroinflammatory disorders of the central nervous system is the inaccessibility of the organ. Thus investigation is limited to end-stage disease and systemic changes that occur during disease progression, neither of which may reflect the pathological process in the central nervous system. These factors may explain the lack of effective therapies in multiple sclerosis, a common chronic inflammatory disease of the central nervous system. To overcome such limitations approaches using more relevant animal models have been developed to study pathological mechanisms as well as the design of rational therapeutic strategies. This review describes the animal models used to study pathological processes leading to inflammation within the central nervous system that may be operating in multiple sclerosis and the use of these models in the design of more rational therapeutic strategies. RECENT
FINDINGS: The clinical heterogeneity of multiple sclerosis as well as the finding of different pathological patterns suggests that multiple sclerosis may be a spectrum of diseases that may represent different pathological processes. This and the renewed interest in the extent of axonal damage has led to the development of more relevant animal models, such as those in nonhuman primates, that both reflect the spectrum of multiple sclerosis and allow the development of species-specific therapeutic approaches.
SUMMARY: While many animal models are available, the use of relevant animal models that mimic either the different forms of multiple sclerosis or the spectrum of multiple sclerosis is critical to examine those factors, for example genes or proteins, that are of pathogenic relevance and can be used as targets for therapy.

Entities:  

Mesh:

Year:  2003        PMID: 12858076     DOI: 10.1097/01.wco.0000073940.19076.43

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  9 in total

1.  Cerebral interleukin-15 shows upregulation and beneficial effects in experimental autoimmune encephalomyelitis.

Authors:  Xiaojun Wu; Weihong Pan; Yi He; Hung Hsuchou; Abba J Kastin
Journal:  J Neuroimmunol       Date:  2010-04-28       Impact factor: 3.478

2.  Soluble mannosylated myelin peptide inhibits the encephalitogenicity of autoreactive T cells during experimental autoimmune encephalomyelitis.

Authors:  Junda Kel; Judith Oldenampsen; Mariken Luca; Jan Wouter Drijfhout; Frits Koning; Lex Nagelkerken
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

3.  Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory disease.

Authors:  Mercedes Fernandez; Alessandro Giuliani; Stefania Pirondi; Giulia D'Intino; Luciana Giardino; Luigi Aloe; Rita Levi-Montalcini; Laura Calzà
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-08       Impact factor: 11.205

4.  Pathogenic Bacterial Proteins and their Anti-Inflammatory Effects in the Eukaryotic Host.

Authors:  Jun Sun
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-09-01

Review 5.  Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development.

Authors:  Yolanda S Kap; Jon D Laman; Bert A 't Hart
Journal:  J Neuroimmune Pharmacol       Date:  2009-10-14       Impact factor: 4.147

Review 6.  Glutamate receptors in neuroinflammatory demyelinating disease.

Authors:  Christopher Bolton; Carolyn Paul
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

7.  Induction of experimental autoimmune encephalomyelitis with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant in three non-human primate species.

Authors:  Krista G Haanstra; S Anwar Jagessar; Anne-Laure Bauchet; Mireille Doussau; Claire-Maëlle Fovet; Nicole Heijmans; Sam O Hofman; Jennifer van Lubeek-Veth; Jeffrey J Bajramovic; Yolanda S Kap; Jon D Laman; Hélène Touin; Laurent Watroba; Jan Bauer; François Lachapelle; Che Serguera; Bert A 't Hart
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-03       Impact factor: 4.147

Review 8.  Bowman-Birk Inhibitors: Insights into Family of Multifunctional Proteins and Peptides with Potential Therapeutical Applications.

Authors:  Agata Gitlin-Domagalska; Aleksandra Maciejewska; Dawid Dębowski
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-25

9.  Suppression of experimental autoimmune encephalomyelitis by extracellular adherence protein of Staphylococcus aureus.

Authors:  Changping Xie; Pilar Alcaide; Brian V Geisbrecht; Darius Schneider; Mathias Herrmann; Klaus T Preissner; Francis W Luscinskas; Triantafyllos Chavakis
Journal:  J Exp Med       Date:  2006-04-03       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.